InStem And Curie Institute Scientists Develop Molecular Sensor To Detect Cancer Drugs

Mumbai : The Institute for Stem Cell Science and Regenerative Medicine (InStem), Bengaluru in collaboration with Curie Institute, Orsay, France, has developed a molecular sensor, which can identify cancer drugs by detecting how such chemicals modify microtubules inside living cells.

Microtubules are part of the cytoskeleton, a structural network within the cell’s cytoplasm, and they alter in response to several chemicals.

“Understanding tubulin modifications have remained a challenge till date because of unavailability of tools that can mark them in living cells. Both the researchers have overcome this shortcoming and developed the first tubulin nanobody – or sensor to study the dynamics of microtubule modifications in living cells and use this for identification of new cancer therapeutic drugs”, said the statement issued by the Department of Science and Technology (DST).

The researchers from Bengaluru and Orsay devised a method to design synthetic proteins, known as nanobodies, which can bind specifically to modified microtubules. These nanobodies are similar to antibodies made in our body as a defense mechanism against pathogens. However, unlike antibodies, the nanobodies are smaller in size and easily amenable for protein engineering. The nanobody was then coupled with a fluorescent molecule to serve as a detection tool, called sensor. They developed and validated a live cell sensor against a unique microtubule modification called tyrosinated form of microtubules that is already known to be important for cell division and intracellular organization.

The tyrosination sensor is the first tubulin nanobody – or sensor – that can be used to study the dynamics of microtubule modifications in living cells. Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA) researchers has shown the application of this sensor in studying the effect of small-molecule compounds that target microtubules. These chemicals are frequently used as anti-cancer drugs. Thus, the tyrosination sensor will facilitate studying microtubule functions for many researchers and will aid identifying new drugs of therapeutic value.

  • Related Posts

    • Pharma
    • April 16, 2024
    • 32 views
    Significant Decline In Pharma Deals In Q1

    NEW DELHI: The pharma and healthcare sector witnessed a significant 15% decline in volume in the first quarter this year, with 47 deals amounting to $ 409 million, as against the…

    • Pharma
    • April 16, 2024
    • 23 views
    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    Ahmedabad: Imagine a bacterial infection with no known cure — a relentless adversary that defies conventional treatments and leads to prolonged illness and hospitalization. This was the condition of nine people…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Significant Decline In Pharma Deals In Q1

    Significant Decline In Pharma Deals In Q1

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments

    Glenmark recalls 6,528 bottles of BP drug in US

    Glenmark recalls 6,528 bottles of BP drug in US

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    CAHO Naa Patients Se Pyaar Hai

    CAHO Naa Patients Se Pyaar Hai